Scientists use manganese to peek inside 'Broken Hearts'

NCT ID NCT07491718

Recruiting now Knowledge-focused Sponsor: University of Edinburgh Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to better understand takotsubo cardiomyopathy, also known as broken heart syndrome, by using manganese-enhanced MRI scans. Researchers will test how different heart medications affect manganese uptake in the heart muscle. The study involves 100 adults who have had takotsubo cardiomyopathy and will compare the effects of bisoprolol, valsartan, sacubitril/valsartan, dapagliflozin, or no medication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Bisoprolol, Valsartan, Sacubitril/Valsartan, Dapagliflozin
What this could lead to: If successful, this could reveal which medications best help the heart recover after takotsubo cardiomyopathy, potentially improving treatment guidelines.
What could go wrong: This is an early-stage observational study with only 100 participants, so results may not apply to all patients. The medications tested are already approved, so no new drug discovery is expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TAKOTSUBO CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Tako-tsubo cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TAKOTSUBO CARDIOMYOPATHY

Contacts and locations

Locations

University of Edinburgh
RECRUITING

Edinburgh, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.